Equities

Vcanbio Cell & Gene Engineering Corp Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Vcanbio Cell & Gene Engineering Corp Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)25.00
  • Today's Change-0.45 / -1.77%
  • Shares traded4.86m
  • 1 Year change+19.62%
  • Beta1.3324
Data delayed at least 15 minutes, as of Feb 13 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Vcanbio Cell & Gene Engineering Corp Ltd is a China-based company mainly engaged in the business of precision prevention, precision diagnosis and cell therapy. The Company operates two segments, including the service segment and the manufacturing segment. The Company’s products and services include cell testing preparation and storage services, research & development (R&D), production and sales of in vitro diagnostic raw materials, in vitro diagnostic reagents and medical devices, R&D, production and sales of biological genes, proteins, antibodies, pharmaceutical intermediates, and comprehensive agents for experiments, as well as genetic testing services. The Company mainly conducts businesses within the domestic market.

  • Revenue in CNY (TTM)1.47bn
  • Net income in CNY74.75m
  • Incorporated1995
  • Employees2.01k
  • Location
    Vcanbio Cell & Gene Engineering Corp LtdNo.45 Dongjiu AvenueAirport Economic AreaTIANJIN 300384ChinaCHN
  • Phone+86 2 258617160
  • Fax+86 2 258617161
  • Websitehttps://www.vcanbio.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shanghai Haohai Biological Tech Co Ltd2.52bn384.21m9.77bn2.16k27.801.87--3.871.651.6510.8324.490.35121.537.841,169,728.004.944.585.965.2669.1370.3914.0714.673.24--0.065642.371.6410.951.042.55-1.8614.87
Qingdao Haier Biomedical Co Ltd2.26bn255.88m10.33bn2.81k40.072.39--4.560.81440.81447.2113.640.40084.315.12806,199.104.6810.875.9214.1245.3149.2111.6724.082.41--0.020528.140.128817.67-9.7115.03-5.5321.16
Xiangyu Medical Co Ltd773.93m73.51m10.92bn2.34k142.595.39--14.120.47890.47895.0712.670.25481.0111.40330,597.702.358.543.2610.1765.9866.789.2228.370.9871--0.238732.49-0.171711.71-54.68-4.4183.55--
Shanghai Microport EP MedTech Co Ltd458.70m52.26m11.00bn500.00210.456.14--23.980.1110.1110.97473.810.23951.336.85917,403.002.730.90842.910.957958.2464.9511.394.0910.17--0.00320.0025.5128.61815.36--35.67--
Beijing Wandong Medical Technolgy Co Ltd1.62bn14.41m11.10bn1.19k947.782.37--6.850.01670.01672.266.660.29372.732.991,360,016.000.26234.510.3045.2131.5942.820.893314.914.80--0.003943.2523.269.18-16.54-1.40-1.3921.06
Sansure Biotech Inc1.67bn271.49m11.19bn2.35k43.621.57--6.700.44270.44272.4512.310.18521.042.46711,687.902.5021.182.8124.3773.7068.6013.4940.514.49--0.171625.7444.7831.89-24.2347.5065.28--
TINAVI Medical Technologies Co Ltd274.20m-159.01m11.43bn307.00--9.15--41.67-0.3493-0.34930.60352.740.16732.187.63893,155.40-10.37-8.02-11.54-9.1670.0969.64-62.01-63.512.94-15.750.1408---14.85-4.8722.54--12.71--
Eyebright Medical Technlgy (Bjng) Co Ltd1.48bn360.97m11.51bn2.29k31.604.09--7.781.881.887.7114.530.40481.893.34644,799.409.9010.5011.5412.0462.9175.1324.4531.923.2824.660.175320.1148.2448.5127.7742.2518.40--
Shandong Weigao Orthopaedic Devce Co Ltd1.48bn266.86m11.53bn2.07k43.192.83--7.810.66720.66723.7010.180.29190.77985.17714,278.405.369.006.5811.0564.2274.0718.3724.984.28--0.001122.9013.18-1.5999.22-12.72-3.40--
Vcanbio Cell & Gene Engineering Corp Ltd1.47bn74.75m11.70bn2.01k151.753.15--7.950.16470.16473.297.930.27781.922.35730,874.401.071.241.511.7667.2968.073.854.201.604.900.02190.00-0.27052.71-5.7315.09-11.35--
Shanghai MicroPort Edvcl MdTch Grp CoLtd1.25bn377.82m11.95bn832.0031.123.02--9.553.123.1210.2732.100.26941.563.661,515,185.007.9415.389.1016.8768.1075.3829.4541.854.36--0.004346.521.6129.301.9628.7858.5335.76
Beijing Hotgen Biotech Co Ltd434.45m-259.33m12.68bn903.00--4.32--29.18-3.04-3.044.9831.630.13131.964.23481,114.30-7.9721.79-8.4724.9356.3855.43-60.7129.144.77--0.016844.35-6.7419.41-760.40---10.29--
Data as of Feb 13 2026. Currency figures normalised to Vcanbio Cell & Gene Engineering Corp Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

6.57%Per cent of shares held by top holders
HolderShares% Held
Hwabao WP Fund Management Co., Ltd.as of 30 Jun 202512.08m2.58%
China Southern Asset Management Co., Ltd.as of 30 Jun 20253.49m0.75%
Zhong Ou Asset Management Co., Ltdas of 30 Jun 20253.40m0.73%
GF Fund Management Co., Ltd.as of 30 Jun 20252.52m0.54%
China Universal Asset Management Co., Ltd.as of 30 Jun 20252.20m0.47%
China Asset Management Co., Ltd.as of 30 Jun 20252.11m0.45%
Guotai Asset Management Co., Ltd.as of 30 Jun 20251.53m0.33%
The Vanguard Group, Inc.as of 04 Feb 20261.33m0.28%
Galaxy Asset Management Co., Ltd.as of 30 Jun 20251.07m0.23%
Maxwealth Fund Management Co., Ltd.as of 30 Jun 20251.02m0.22%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.